New hope for rare, aggressive tumors: cabozantinib trial shows promise
NCT ID NCT04412629
First seen Dec 10, 2025 · Last updated May 08, 2026 · Updated 24 times
Summary
This study tests the drug cabozantinib in 35 adults with high-grade neuroendocrine tumors that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors and help people live longer. Cabozantinib works by blocking signals that help tumors grow and form blood vessels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE NEUROENDOCRINE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.